Neurohumoralactivation refers to increased activity of the sympathetic nervous system, reninangiotensin system, vasopressin and atrial natriuretic peptide. It is nowknownthat neurohumoral activation contributes to the transition from ventricular dysfunction to clinical heart failure, and is an independent predictor of poor prognosis in heart failure. Although the treatment of heart failure has traditionally focused on drugs to improve ventricular function, there is increasing evidence that therapeutic modulation of neurohumoral activation is a key to successful treatment of heart failure. For example, there is mounting evidence that angiotensin converting enzyme inhibitors (the unquestioned cornerstone for treatment of heart failure), beta receptor blockers, digitalis, and endurance exercise training exert their benefit in heart failure in large part through neurohumoral modulation. This observation -discussed in this brief review -highlights the concept that compensatory neurohumoral activation to decreased cardiac function mayitself contribute to the developmentof heart failure and its poor prognosis.
Introduction
In the past, treatment of heart failure focused on improving left ventricular function directly with positive inotropic drugs. Therefore, it mayseem counterintuitive that most positive inotropic therapies increase mortality, whereas negative inotropic beta-adrenergic blockers appear to have beneficial effects in heart failure. In contrast to the disappointing effects of manypositive inotropic drugs, controlled clinical trials demonstrated that therapy with angiotensin converting enzyme inhibitors (ACEI) improve survival in patients with heart failure. Indeed, the striking benefit with ACEInow mandates administration of ACEIto all patients with left ventricular dysfunction in the absence of intolerable side effects. Initially, the benefit of ACEI was attributed to their vasodilator actions, but evidence is mounting that their benefit is largely due to neurohumoral rather than vasodilator actions.
This emphasizes the importance of neurohumoral activation in heart failure. But what is meant by neurohumoral activation? What is the evidence that it is detrimental in heart failure? What causes it? Finally, how does treatment modify it?
What is "neurohumoral activation?"
In simplest terms, neurohumoralactivation characterizes a state in which the neural and hormonal systems designed to maintain adequate organ perfusion are turned on to excessively high levels. This activation may include the sympathetic nervous system (SNS), renin-angiotensin-aldosterone-system, vasopressin, and atrial natriuretic peptide. Although initially this is an adaptive response to cardiac injury, prolonged activation of these support systems inevitably leads to progressive heart failure symptomsand ultimately cardiac death. Heart failure patients with the greatest SNS activation, as estimated by plasma norepinephrine levels, have the worst overall survival (1) .
SNSactivation is present early in the course of left ventricular dysfunction. In an animal model of early left ventricular dysfunction without overt heart failure, plasma norepinephrine levels are elevated, indicative of early SNS activation (2) . Power spectral analysis of heart rate variability suggests that there is sympathetic activation early in the course of left ventricular dysfunction in a canine model of heart failure (3). This finding of sympathetic activation with ventricular dysfunction in the absence of heart failure has also been demon-Neurohumoral Activation in Heart Failure 500 g250 Controls p<0.05
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NoHF HF Figure 1 . Evidence for increases in plasma norepinephrine (NE) in patients with left ventricular dysfunction (LVD) even before symptomsof heart failure (HF). There is a further increase in NEin patients with symptomatic heart failure (4). Figure 2 . Evidence for increased cardiac sympathetic activity before generalized sympathetic excitation and before sympathetic activation to the kidney in patients with heart failure.
Individual and mean ± SEMvalues for cardiac norepinephrine (NE) spillover, renal NE spillover, total-body NE spillover in healthy controls and in patients with mild to moderate and severe heart failure (CHF) are presented (adapted from Rundqvist et al (5)). strated in humans. Francis et al found that plasma levels of norepinephrine are elevated in patients with left ventricular dysfunction even in the absence of symptomatic heart failure (4) (Fig. 1 ). Using the technique ofmicroneurography to record muscle sympathetic nerve activity directly from a peroneal nerve in awake humans, Grassi and colleagues (6) found that even in patients with mild heart failure, sympathetic nerve activity to the muscle circulation is increased. Interestingly, patients with heart failure secondary to diastolic dysfunction do not have elevated plasma norepinephrine (5). These findings indicate that the neurohumoralexcitation reflects systolic ventricular dysfunction and not simply clinical heart failure. The first organ to be targeted by this increased SNS activation is the heart (7). Cardiac adrenergic activity can be measured using metaiodobenzylguanidine (an analogue of the adrenergic agonist guanethidine) and iodine-123 (123I-MIBG). Studies with this method indicate that cardiac sympathetic nerve activity is increased in patients with heart failure at a time when volume and pressure overload are not present (8). Norepinephrine spillover is an alternate meansto measureorganspecific sympathetic activation. In patients with mild heart failure, cardiac sympathetic nerve activity is increased threefold above control (7) before increased sympathetic activity to the kidney or muscle circulations (Fig. 2) . Thus, SNSoccurs early in the course of left ventricular systolic dysfunction. The first organ targeted is the heart, but the kidney and muscle circulation are In what wayis sympathetic nervous system activation detrim en ta l? Initially an adaptive response to cardiac injury, prolonged activation of the sympathetic nervous system mayhave adverse sequelae (Fig.-3) (9). These include increased myocardial wall tension and ischemia. Norepinephrine is directly cardiotoxic, and may lead to detrimental cardiac remodeling. Peripheral vasoconstriction leads to increased afterload and diminished cardiac output and renal perfusion, leading, in turn, to increased sodium and fluid retention. The renal sympathetic nerves also act directly on the renal tubules to promote sodium retention.
Finally, sympathetic nerve activation decreases ventricular fibrillation threshold, predisposing to sudden death. As noted above, heart failure patients with the greatest sympathetic activation have the poorest prognosis (1).
What are the mechanismsunderlying sympathetic activation in heart failure?
Although there is agreement that the SNS is activated in heart failure, there is controversy about the mechanismsunderlying this activation. Possible mechanisms implicated include 1) attenuation of tonically inhibitory input to the central nervous system; 2) activation of excitatory input to the central nervous system; and/or 3) changes in humoral or local brain factors affecting central neural sympathetic regulation (Fig. 4) Dibner-Dunlap and Thames (10) recorded renal sympathetic nerve activity in sinoaortic denervated dogs with pacing-induced heart failure. During volume expansion, there was impairment of cardiopulmonary baroreceptor mediated suppression of renal sympathetic nerve activity (10). DiBona and Sawin (1 1) measured baroreceptor nerve activity directly in a rat model of heart failure. During changes in arterial pressure or left ventricular filling pressure, arterial and cardiopulmonary baroreceptor activity was significantly depressed (1 1). These studies, and others, are consistent with abnormal baroreflex control of sympathetic nerve activity in heart failure. This abnormality would lead to heightened sympathetic activity. In humans, there is also compelling evidence that abnormal baroreceptor restraint contributes to heightened sympathetic activity in heart failure. First, sympathetic nerve activity is elevated only to those organs and tissues subject to baroreflex restraint in heart failure and not to all organs and tissues (12, 13). For example, SNSactivation directed to muscle circulation, which is under baroreflex control, is elevated (6, 12, 14) . In contrast, sympathetic nerve activity directed to skin, a tissue free from baroreflex control, is not elevated, even in patients with advanced heart failure (12) (Fig. 5) . Second, sympathetic neural responses to baroreceptor modulation are abnormal in heart failure patients ( 1 5), even those with mild heart failure (6). This blunted baroreflex restraint would lead to elevated sympathetic traffic.
In summary, animals and humans with heart failure have marked sympathetic activation at rest, and attenuated baroreflex control ofsympathetic nerve activity. Thesefindings arepresent early in the course of left ventricular dysfunction, and are consistent with the concept that abnormal baroreflex control of sympathetic nerve activity underlies the sympathetic excitation that characterizes heart failure.
What is the effect ofACEl on survival in heart failure? Although muchremains to be learned about the mechanisms of the neurohumoral activation in heart failure, it is firmly . Direct intraneural recordings of muscle and skin sympathetic nerve activity (SNA). Simultaneous muscle and skin neurograms in a representative control subject (top two tracings) and in a representative heart failure patient (bottom two tracings) are shown. Muscle sympathetic nerve activity is markedly increased in the heart failure patient compared with the control subject. In contrast, skin sympathetic nerve activity is not increased in the heart failure patient (from Middlekauff, et al (10)).
Internal Medicine Vol. 37, No. 2 (February 1998) established that ACEIimprove survival in heart failure, mandating ACEI therapy in all patients with left ventricular dysfunction in whomthese drugs are tolerated and not contraindicated (Table 1 ). The Cooperative North Scandinavian Enalapril Survival Study-I (CONSENSUS I) was the first randomized controlled trial to demonstrate that enalapril improved survival in advanced heart failure (16). The Veterans Administration Heart Failure Trial II (V-HeFT II) showed that enalapril was superior to hydralazine and isosorbide dinitrate in improving survival in mild to moderate heart failure (17). The Hydralazine-Captopril (Hy-C) trial extended these findings to patients with advanced heart failure; this study demonstrated improved survival with captopril compared to hydralazine despite similar hemodynamics on each therapy (18). The Studies of Left Ventricular Dysfunction (SOLVD) treatment trial ( 19) found that enalapril comparedto placebo improvedsurvival in patients with symptomatic left ventricular dysfunction (LVEF <35%). In the SOLVDprevention trial, enalapril decreased the progression to heart failure in patients with left ventricular dysfunction without overt heart failure (20) ; these patients have sympathetic overactivity as evidenced by elevated plasma norepinephrine even in the absence of symptomatic heart failure (4).
The Survival and Ventricular Enlargement (SAVE) trial demonstrated that following a myocardial infarction, patients with left ventricular dysfunction (left ventricular ejection fraction <40%)who were treated with captopril compared to placebo had improved survival (21). The results of ISIS-4 and GISSI-3 demonstrated improved survival in all survivors of myocardial infarction (regardless of ventricular function) who were randomized to ACEIcompared to placebo; these studies further extended the indications for ACEI (22, 23) . In summary,in the above trials, and numerousothers (24-27), ACEIhave I) prevented progression to heart failure in patients with mild left ventricular dysfunction without overt heart failure and 2) improved survival in patients following myocardial infarction, as well as in patients with mild to advanced heart failure.
Howdo ACEI improve survival in heart failure? Weare able to glean someinsights into the mechanismsof survival benefit of ACEI therapy by examining results from these large randomized trials. The benefits do not appear to be attributable to hemodynamiceffects alone, because other vasodilators, titrated to similar hemodynamicresponses, do not show the same survival benefit (1 8). Markers of neurohumoral activation were reported in several of these trials. In the CONSENSUStrial (16), enalapril was associated with a significant reduction in plasma norepinephrine by 6 weeks of therapy. Interestingly, enalapril was most effective in improving survival in the heart failure patients with the greatest elevation in neurohormones. In the SOLVDtreatment trial (20), enalapril therapy was associated with a reduction in plasma norepinephrine levels compared to placebo. In summary, ACEIreduce plasma norepinephrine levels which suggests that a beneficial effect on the sympathetic nervous system may contribute to its beneficial effects on survival.
What are the mechanisms of ACEIinteractions with the SNS?
There are many potential mechanisms by which ACEI therapy modulates SNSactivity; the specific ones which are responsible for the favorable effects of ACEI therapy in heart failure remain to be clarified (Fig. 6) Experimental evidence supports the role of several of these mechanisms in heart failure patients. In a trial of acute ACEI therapy in humans with heart failure, Dibner-Dunlap and colleagues (30) found that intravenous enalaprilat improved arte- sympathetic nerve activity and baroreflex activity in patients with heart failure. Following 2 months of ACEI therapy with benazepril, resting sympathetic nerve activity was markedly reduced. Baroreflex restraint of muscle sympathetic nerve activity and heart rate was markedly enhanced. These findings support the concept that blunted baroreflex control underlies the sympathetic excitation in heart failure, and that therapy with ACEI restores baroreflex control towards normal in heart failure patients. Takeishi and colleagues (32) used 123I-MIBG to measure cardiac sympathetic nerve activity in heart failure patients treated with enalapril compared to placebo. Cardiac sympathetic nerve activity, like muscle sympathetic nerve activity, is governed by baroreflexes. Patients were studied before and after treatment for a meanof nine months. Cardiac sympathetic nerve activity was significantly reduced in the enalapril group but not the control group. Thus, sympathetic influences on the heart are decreased on enalapril therapy. In summary, evidence is accumulating that ACEImodulate the SNSthough baroreflex pathways. There is also evidence that ACEImay act to reduce sympathetic drive through a reduction in angiotensin levels in crucial brain centers involved in sympathetic regulation. Do ACEIand angiotensin II receptor antagonists have similar efficacy in heart failure? A new class of drugs has recently become available for the treatment of humanswith heart failure -the angiotensin II receptor blockers (AT receptor blockers). The AT receptor blockers that have been introduced into clinical practice block AT-1 receptors and spare AT-2 receptors. Most of the detrimental effects ofangiotensin are medicated through AT-1 receptors. The physiological significance of AT-2 receptor activation is unknown, but beneficial effects have been suggested. In what ways do AT-1receptor blockers and ACEIdiffer? ACEIincrease bradykinin in addition to decreasing angiotensin II. In contrast, the AT-1 receptor blockers do not alter bradykinin levels or actions. ACEI do not interrupt formation of angiotensin through alternative (non ACEdependent) synthetic pathways. In contrast, the AT-1 receptor antagonists block the actions of angiotensin formed through both ACEand non-ACE dependent pathways. As mentionedpreviously the AT-1 receptor blockers spare effects ofangiotensin on AT-2receptors whereas ACEIwould reduce angiotensin stimulation of both AT-1 and AT-2 receptors. Thus, although both AT-1 receptor blockers and ACEIact to modulate angiotensin actions, there are potentially important differences in these two classes of drugs. At this time, it is unclear if functional and survival benefits ofACEI will be shared by the AT-1 receptor blockers. Preliminary studies with AT-1 receptor blockers appear promising. In a study of heart failure produced by coronary ligation in rats, survival was equivalent with the AT-1 receptor antagonist, losartan, compared to captopril (an ACEI) (33). There has been one randomized study of AT-1 receptor blockers in humans with heart failure (34). In this study called the Evaluation of Losartan in the Elderly Study (ELITE), heart failure patients >65 years were randomized to losartan or captopril with the primary endpoint being renal function, and the secondary endpoint being survival (34). There was no difference in the incidence of renal insufficiency (10.5% in both groups). Unexpectedly, however, at 48 weeks survival was better in the losartan group (34). Larger trials are nowin progress to confirm these intriguing preliminary findings.
What is the role of beta-adrenergic blockade? Recognition of the detrimental effects of sympathetic activation in heart failure has led to interest in beta-adrenergic blockade for the treatment of heart failure. Initial studies, although small and lacking adequate controls, reported clinical improvement and prolonged survival with beta-blockade in heart failure (35-37).
In larger, controlled trials with betablockers, an improvementin left ventricular ejection fraction on beta-blockers has been demonstrated, but not an improvement in survival (38, 39). In the Metoprolol in Dilated Cardiomyopathy study, 383 New York Heart Association (NYHA) Class II and III heart failure patients with idiopathic dilated cardiomyopathywere randomizedto placebo or metoprolol, a beta-1 selective antagonist (38). Left ventricular ejection fraction was significantly improved on therapy, but survival was not. In the Cardiac Insufficiency Bisoprolol Study (39), 641 NYHAClass III heart failure patients with ischemic and idiopathic etiologies were randomized to bisoprolol, a beta-1 selective antagonist, or placebo. Bisoprolol therapy was associated with improved functional class and fewer hospitalizations for heart failure, but no improvement in survival. Several studies of a third generation beta-blocker, carvedilol, have reported an improvement in functional class, ejection fraction and survival (40-43), although the improved survival has been questioned in an editorial commentary (44). It should be noted that carvedilol has alpha-1 -adrenergic blocking, antioxidative and antiproliferative properties in addition to beta blocking properties, and someof its benefit could accrue from these other actions. Larger studies of beta-blockers in heart failure, empowered to determine more definitively a survival benefit, are currently ongoing. In each of these trials, beta-blockers were carefully titrated, and have been well tolerated with <4%patients withdrawn early due to heart failure exacerbation. However, at this time, due to their potentially catastrophic acute effects, the use of beta-adrenergic blockers in heart failure should remain in the domain of the cardiologist with expertise in heart failure. Beta-blockers antagonize the SNSat the beta-receptor level, but not equivalently. Metoprolol is a beta-1 selective antagonist, and is associated with upregulation of the beta-1 receptor (45). In contrast, carvedilol is a nonselective beta-blocker which interacts with G proteins leading to downregulation of beta-1 and beta-2 receptors (46).
In addition to their benefits at the receptor level, there is intriguing data to suggest a beneficial effect of beta-blockers on central SNS outflow. Chronic carvedilol therapy in heart failure patients has been associated with a fall in plasma norepinephrine levels. In patients with hypertension, chronic beta-blockade reduces central SNSoutflow (47). In a small study of metoprolol therapy in patients with heart failure, a marked reduction of muscle sympathetic nerve activity was reported after a mean follow-up of 20 months (48). The mechanism of the reduction in central SNS outflow associated with betablockers is unknown.
In summary, beta-blocker therapy in heart failure is associated with an improvement in ejection fraction. Somewhat surprisingly, in addition to decreasing beta receptor influences on the heart, chronic beta receptor blockade mayreduce sympathetic activity to other tissues and organs. The benefits of beta-blockers on survival remain controversial. At this time, because ofpotential acute catastrophic effects, the use of beta blockers in heart failure should remain in the domain of a cardiologist with expertise in heart failure.
Is there still a role for digoxin in heart failure? For decades, digitalis was the mainstay of the treatment of heart failure despite the absence of controlled clinical trials of its efficacy and safety. Digitalis was initially used for its positive inotropic properties, but the inotropic effect of digitalis is modest, and the value and safety of inotropic agents in heart failure have been challenged. Further, digitalis has a relatively narrowtherapeutic range before toxicity. Therefore, the role of digitalis in heart failure was questioned. However, recently several small, short-term controlled studies in heart failure patients already treated with ACEIdemonstrated that withdrawal of digoxin is associated with heart failure exacerbation and worsening functional capacity (49, 50). In the Digitalis Investigation Group (DIG) trial, empowered to demonstrate mortality effects, digitalis compared to placebo was not associated with improvement (or reduction) in survival in heart failure patients already treated with ACEI (51). The DIG study did, however, confirm that digitalis reduced heart failure exacerbation episodes requiring hospitalization. The beneficial effect of digitalis in heart failure is likely not attributable to its inotropic effects (which are modest), but to its neurohumoral effects. In animals, digitalis sensitizes baroreceptors, thereby inhibiting sympathetic nerve activity (52). These baroreceptor actions that produce sympathetic inhibition are more pronounced in dogs with heart failure than in normal dogs. Digitalis also has neuromodulatory effects in humans. Acute digitalis administration in humans with heart failure inhibits sympathetic nerve activity, measured by microneurography ( Fig. 7) (53) and by cardiac norepinephrine spillover (54). This effect is independent of hemodynamic responses. Chronic digitalis administration has similarly favorable neurohumoral effects. In dogs, chronic digitalis administration produces sustained sensitization of cardiac baroreceptors (55). In humans, chronic digitalis is associated with a reduction in plasma norepinephrine levels (56). In summary, digitalis therapy has favorable neurohumoral effects in heart failure, including a sustained decrease in sympathetic activity. It is associated with a reduction in heart failure exacerbations, but not with improved survival.
What should we tell our patients with heart failure about exercise?
Exercise intolerance is a hallmark of congestive heart failure. Because of this and a concern about safety, endurance exercise training has not commonly been recommended for patients with heart failure. Surprisingly, there is strong rationale for exercise training in patients with heart failure (57). The reduction in exercise capacity in patients with heart failure is related more to abnormalities in the peripheral circulation and skeletal muscle than to the magnitude of ventricular dysfunction. Heart failure is accompanied by skeletal muscle atrophy and abnormalities in skeletal muscle that resemble deconditioning (58). These patients also have impairment in skeletal muscle blood flow during exercise that results, in part, from increased neurohumoral activation (59). Heart failure is also characterized by an increased ratio of sympathetic to parasympathetic activity, which may increase the risk of sudden cardiac death. Endurance exercise training acts to reverse many of these abnormalities in skeletal muscle, the peripheral circulation and the autonomic nervous system. Exercise training does not improve ventricular function, but as discussed previously this maynot be essential for effective treatment of There are several controlled clinical trials of endurance exercise training in patients with chronic heart failure and severe left ventricular dysfunction. These trials range from 3 to 24 weeks (60-63); there are uncontrolled trials extending for 19 months (64). Virtually uniformly, these studies demonstrate an increase in exercise duration and peak oxygen consumption. This benefit is related to peripheral neurohumoral and circulatory adaptations and not to improvement in ventricular function. Exercise training promotes a reduction in resting sympathetic activity and enhances vagal tone in patients with heart failure (60, (64) (65) (66) (67) . A transient sympathetic modulating effect has even been observed after a single bout of endurance exercise in patients with heart failure (68). In addition, exercise training enhances skeletal muscle blood flow and the ability of skeletal muscle to extract and utilize oxygen during exercise. In summary, enduranceexercise training increases exercise tolerance andpeak oxygenconsumptionin patients with heart failure. This effect results from favorable neurohumoral and peripheral circulation adaptations. It is not knownif exercise training improves survival, but a long term (12 month) controlled clinical trial of the effects of exercise training on functional capacity and quality of life is reportedly underway. In the meantime, there is sufficient rationale and evidence to support the benefit and safety of endurance exercise training as an djunct to establishedpharmacological therapy in heartfailure.
Summary
Heart failure is characterized by neurohumoral activation. The heart failure patients with the greatest activation of the sympathetic nervous system have the poorest survival. Sympathetic neural activation contributes to the progression of left ventricular dysfunction, renal sodium retention, the development of clinical heart failure, and susceptibility to malignant ventricular arrhythmias. The mechanismsunderlying activation of the sympathetic nervous system are not entirely clear, but evidence supports a major role for impaired baroreflex function. Normally, baroreflexes tonically restrain sympathetic nerve activity; in heart failure patients, this restraint is attenuated. Angiotensin converting enzyme inhibitors impede the progression of heart failure, and improve survival in heart failure patients. These beneficial effects are largely due to the neurohumoral actions of ACEI, including interactions with the sympathetic nervous system. Therapy with ACEIdiminishes sympathetic nervous activation in heart failure. It is not known if angiotensin II receptor antagonists (AT-1 receptor antagonists) will have similar beneficial effects in heart failure, but early reports appear promising. In patients with heart failure already treated with ACEI, addition of beta-blocker therapy is associated with an improvement in ejection fraction. Carvedilol, a third generation beta receptor blocking drug with additional properties, has been reported to improve survival, but this finding has been challenged, and studies empowered to determine impact of beta blockers on survival are ongoing. Digitalis added to ACEItherapy is safe, improves exercise tolerance and decreases the incidence of heart failure exacerbation requiring hospitalization. The beneficial effects of digitalis are likely due to its neurohumoral, and not inotropic, effects. Digitalis does not improve survival. Exercise training in patients with heart failure is surprisingly well tolerated and is associated with improved exercise tolerance and oxygen consumption and modulation of neurohumoral activation, but survival benefits are unknown.
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